LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme. The company is struggling with several headwinds as it works to develop its obesity plan.
A Rough Day for "Dividend Knights" Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped.
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country' President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.
Eli Lilly Earnings: What To Look For From LLY Global pharmaceutical company Eli Lilly (
NYSE:LLY )
will be reporting earnings this Thursday before the bell. Here’s what investors should know.
IPO Stock Hinge Health Surges Despite Lackluster Second-Quarter Sales The company, which went public in May, provides AI-powered physical therapy through a mobile application.
Inspire Medical Plunges On Outlook Cut, Weak V System Rollout: Analysts React Inspire Medical stock falls as Q2 earnings beat is overshadowed by guidance cut and slower U.S. rollout of its newly approved Inspire V system.
The 8 Best Stocks to Buy Now in August (2025) Whether you're looking for growth stocks, dividend stocks, or artificial intelligence stocks, there is something for you in this incredible list.
Novo Nordisk Stock Sinks—But Is a Bottom Finally In? Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings
Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug.
Eli Lilly Reverses Early Weakness, Closes Near Day's High After Key Trading Signal A significant trading signal flashed for Eli Lilly (LLY) at a price of $755.87, after which LLY rose up to 1.8% and closed near its intra-day high.
Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On? Hims & Hers Health Inc. (
NYSE: HIMS ) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.
This Biotech Stock Could Soar on Upcoming Clinical Data This weight loss drugmaker may be significantly undervalued right now.
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics.
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave In a notable shift, shares of Pfizer (
NYSE: PFE ) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,
Why Eli Lilly Stock Topped the Market Today Zepbound could benefit handsomely if an apparently planned government program is implemented.
Why Novo Nordisk Stock Bumped Higher on Friday There might be a new way for certain users to defray their costs for obesity treatments.
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro, and Zepbound for patients for “weight management” purposes as per the plan.
